Infectious Diseases Announcements

FREE Carbepenem Resistance Testing

Carbapenem-resistant Acientobacter (CRAB) is an important nosocomial pathogen causing high mortality and morbidity in debilitated patients worldwide. CRAB most frequently expresses carbapenemases belonging to the class D OXA β-lactamases group. Commonly used phenotypic tests do not display optimal sensitivity and specificity for the detection of CRAB and therefore are not employed for surveillance. In addition no commercial molecular assay for the detection of non-OXA 48-like OXA carbapenemases. UPHL has now implemented a multiplex test developed at CDC to fill this diagnostic gap!
This PCR assay can detect carbapenemases belonging to the OXA-23-like, OXA-24/40-like and OXA-58-like groups in CRAB and other gram negative organisms. This test is validated for molecular characterization of bacterial isolates only and is performed for free within the State’s carbapenemase resistance surveillance program.

HCV Quantitation now offered

Beginning March 15, 2019, UPHL will offer a nucleic acid amplification test (NAAT) for detection of the Hepatitis C virus (HCV) and quantitation of viral loads. We have validated and implemented the Aptima HCV Quant Dx assay by Hologic. This is an FDA approved NAAT based on transcription mediated amplification with a lower limit of quantification of 10 IU/mL. The implementation of this test at UPHL will allows us to verify positive serological results and perform the CDC-recommended algorithm entirely in house. UPHL will be also be able to assist in Pre-treatment and On-treatment monitoring. Please note that the Aptima HCV Quant Dx assay is not approved for use as a screening test for the presence of HCV in blood products.  The test is performed once a week on Fridays and results will be provided between 1 to 7 days from receipt of the specimen. The cost of this test is $75.

For more information on specimen and transport information, please click here.